Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2

Malipiero, Giacomo; D’Agaro, Pierlanfranco; Segat, Ludovica; Moratto, Anna; Villalta, Danilo

doi:10.1016/j.cca.2021.11.023

Cited by 18 publications

(19 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Stamatopoulou et al, in a cohort of 142 infection-naïve healthcare workers, found that the total mean of anti-SARS-CoV-2 IgG levels decreased significantly four months following the second dose 21 . Also, Malipiero et al 22 and Matusali et al 23 , in health care workers who underwent COVID-19 vaccination, showed a marked decline in anti-RBD-IgG levels at six months. Padoan et al showed a reduction of 90% in anti-SARS-CoV-2 IgG antibody levels, which was independent of age, gender, and previous infection 24 .…”

Section: Discussionmentioning

confidence: 95%

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Sasso

Agnello

Giglio

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Immunosurveillance by evaluating anti-spike protein receptor-binding domain (S-RBD) antibodies represents a useful tool to estimate the long immunity against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) infection. The aim of this study was to evaluate the kinetics of antibody response in vaccine recipients. We measured anti-S-RBD IgG levels by indirect chemiluminescence immunoassay on Maglumi 800 (SNIBE, California) in 1013 healthy individuals naïve to SARS-CoV2 infection after two and three COVID-19 vaccine doses. We found that anti-S-RBD IgG levels are higher in females than males. Antibody levels gradually decrease to a steady state after four months since the peak, and the decay is independent of age, sex, vaccine doses, and baseline antibodies titer. The third dose induces a high anti-S-RBD IgG reactivity in individuals with previous high responses and triggers a moderate-high anti-S-RBD IgG reactivity. The assessment of anti-S-RBD IgG levels is essential for monitoring long-term antibody response. A third SARS-CoV-2 vaccine dose is associated with a significant immunological response. Thus, our results support the efficacy of the vaccine programs and the usefulness of the third dose.

show abstract

Section: Discussionmentioning

confidence: 95%

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Sasso

Agnello

Giglio

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…It is also informative that the antibody titres a month after surgery reduced significantly in both groups. This might reflect the natural wane off of an antibody titre reported in the literature [ 10 , 20 , 21 ] with possible acceleration affected by surgical intervention. A decrease of 75–93% IgG titres after 3 weeks to 3 months after second dose vaccination in healthy subjects is reported previously [ 10 , 20 , 21 ].…”

Section: Discussionmentioning

confidence: 90%

“…This might reflect the natural wane off of an antibody titre reported in the literature [ 10 , 20 , 21 ] with possible acceleration affected by surgical intervention. A decrease of 75–93% IgG titres after 3 weeks to 3 months after second dose vaccination in healthy subjects is reported previously [ 10 , 20 , 21 ]. Although standard primary SARS-CoV2 vaccination protocol is twice dosage, a third booster or an additional dose is proposed [ 22 , 23 ].…”

Section: Discussionmentioning

confidence: 90%

Effects of cardiopulmonary bypass on immunoglobulin G antibody titres after SARS-CoV2 vaccination

Hayashi

Takami

Fujigaki

et al. 2022

Interactive CardioVascular and Thoracic Surgery

View full text Add to dashboard Cite

Background Patients with cardiovascular disease are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Although SARS-CoV2 vaccination may be effective, its impact on surgical patients is not well studied. We investigated the effects of cardiovascular surgery, especially under cardiopulmonary bypass (CPB), on the antibody titers after SARS-CoV2 vaccination. Methods A prospective observational study was designed for patients undergoing surgery between July to November 2021. The IgG against the receptor binding domain (RBD-IgG) was measured and antibody preserved rate (APR) was calculated from perioperative titers comparison. Results Enrolled 63 study patients were divided into 39 undergoing surgery with CPB (Group CPB) and 24 without CPB (Group None). Preoperative vaccines were BNT162b2 (Pfizer/BioNTech) (n = 58, 92%) and mRNA-1273 (Moderna) (n = 5, 8%). While RBD-IgG titers did not significantly decrease after surgery in Group None, they decreased significantly in Group CPB from 21.80 [11.15, 37.85] U/ml to 11.95 [6.80, 18.18] U/ml (p < 0.001) a day after surgery, 11.40 [7.85, 22.65] U/ml (p < 0.001) 14 days after surgery, and 7.60 [4.80, 17.60] U/ml (p < 0.001) a month after surgery, respectively. The APRs a day after the surgery were significantly lower in in Group CPB (0.46 [0.41, 0.60]) than in Group None (0.80 [0.68, 0.87]) (p < 0.001). Conclusions The SARS-CoV2 antibody titers significantly decreased with lower APRs immediately after surgery under CPB. Based upon our informative results, careful considerations of vaccination schedule might be required for surgery under CPB. Clinical registration number Fujita Health University Ethics Committee (HM 21-164)

show abstract

“…The measurement of anti-SARS-CoV-2 RBD IgG antibody response is very important in order to define the dynamics of immunization in vaccine COVID-19 recipients. Malipiero et al used a commercial anti-RBD (receptor binding domain) IgG quantitative chemiluminescent immunoassay to investigate the kinetics of anti-SARS-CoV-2 neutralizing antibodies on Pfizer/BioNTech BNT162b2 vaccine in local healthcare workers [13,14]. Another study suggested that the antibody's value of the anti-RBD IgG antibody might reflect the anti-SARS-CoV-2 neutralizing bioactivity to some extent in the body's immune response to COVID-19 inactive vaccination and has a certain application value to explore the immune effect of the vaccinated population for the prevention of COVID-19 infections [15].…”

Section: Discussionmentioning

confidence: 99%

The Fluctuation Trend of Serum Anti-SARS-CoV-2 IgM/IgG Antibodies Seroprevalence in the Non-COVID-19 Infected Population and Correlation with Peripheral Blood Leukocyte Parameters in Beijing, China, 2021: A Real-World Study

et al. 2022

View full text Add to dashboard Cite

Since 2019, the coronavirus disease 2019 (COVID-19) global pandemic has caused more than 300 million cases of disease and 5 million deaths. Vaccination has been widely accepted as the most effective measure for the prevention and control of this disease. However, there is little understanding about serum anti-SARS-CoV-2 IgM/IgG levels after inactivated vaccination as well as the relationship with peripheral blood leukocytes in the non-COVID-19 infected population. A total of 16,335 male and 22,302 female participants were recruited in this study, which was conducted in the Peking University Third Hospital located in Beijing (China). The level and seroprevalence of serum anti-SARS-CoV-2 receptor-binding domain (RBD) IgM/IgG and the association with peripheral blood leukocytes classification were investigated. With an increase in the number and percentage of full immunization of COVID-19 vaccinations in Beijing, serum anti-SARS-CoV-2 IgG antibodies levels and seroprevalence were significantly elevated (p < 0.01). The serum anti-SARS-CoV-2 IgG antibodies of 60 years and older persons were significantly lower than that of individuals that are 18~60 years old (p < 0.01), and there was a positive relationship between serum anti-SARS-CoV-2 IgG antibodies levels and peripheral blood lymphocyte count. The investigation of serum anti-SARS-CoV-2 IgM/IgG antibodies and the peripheral hematological index may prompt and help understand the adaptive immune response of vaccination.

show abstract

Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2

Cited by 18 publications

References 69 publications

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine

Effects of cardiopulmonary bypass on immunoglobulin G antibody titres after SARS-CoV2 vaccination

The Fluctuation Trend of Serum Anti-SARS-CoV-2 IgM/IgG Antibodies Seroprevalence in the Non-COVID-19 Infected Population and Correlation with Peripheral Blood Leukocyte Parameters in Beijing, China, 2021: A Real-World Study

Contact Info

Product

Resources

About